There is currently a great uncertainty on how the patients respond to oncology treatments, especially those who are underrepresented in clinical trials. This causes a good number of complications, some of them severe, which can lead to the hospitalization of patients, hindering their recovery, reducing their quality of life and increasing their hospital costs, which represent a high percentage of expenses per patient. This also impacts the pharmaceutical industry, which requires maintaining competitive performances against every new oncology treatment available in the market.
The Spanish company, created in 2016, is specialized in the healthcare industry whose mission is to reduce patient complications through AI solutions. In this context, the company offers a unique and scalable federated database system in compliance with the data protection regulatory framework. This system benefits not only the customers (Health providers and Pharma), improving their clinical outcomes and reducing uncertainty and unexpected complications and costs by at least 30% by 2023, but also the patients' compliance, improving and tailoring their care and follow-up. It stores every patient’s data which easily allows analysing Real-World Data (RWD) and creates different predictive models, such as those for treatment complications, each offering new monetization capabilities to the company. Moreover, the system is able to develop new, better and targeted ways to treat cancer. The company estimates that the technology will increase patients' compliance rate over 90%.
This system guides the patient during the whole process of its treatment and recovery. It is a mobile application that enables the communication with the doctor and monitors the patient´s symptoms and life quality. By analysing the data provided, the system evaluates the results and effectiveness of treatments for different patient profiles. This manner, the doctor’s decision making is improved as she/he will have the information before the medical consultation and the system will compare the patient’s characteristics with other previous patients with similar symptoms. Moreover, the system is able to make early detections thanks to monitoring and also population analysis where the system is in constant learning. In addition, the application has been certificated since the beginning by medical and legal entities for its feasibility either in the medical treatment and the data protection. It has already been tested in a couple of Basque hospitals and it is implemented in those centres thanks to the positive results. Indeed, the product meets the requirements of the European laws in terms of data acquisition and protection.
The company has already obtained contracts with strategic partners in hospital and pharmaceutical markets: a top5 multinational pharmaceutical company in oncology, the biggest private hospital group in Spain, a top3 biggest public hospital in Spain, a reference public Health System, amongst others. Since its incorporation, the system has obtained over 1M euros total funding and various international awards (i.e., eDeaSalud2018 price of Pfizer Foundation). The company’s objective is to expand across Europe in the next years.
The company is offering this product to healthcare facilities and hospitals with oncology service, preferably, through a commercial agreement with technical assistance in which the company would help the customer in any issue raised but the management of the program would belong to the customer. Cooperation through a license agreement is also envisaged.